Logo
x

Search

Subscribe Now

 Approval

Celltrion’s Omlyclo (CT-P39) Secures the Health Canada’s Approval (Biosimilar, Xolair)

Celltrion’s Omlyclo (CT-P39) Secures the Health Canada’s Approval (Biosimilar, Xolair)

  • December 10, 2024
AOP Health’s Rapiblyk (landiolol) Receives the US FDA’s Approval for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting

AOP Health’s Rapiblyk (landiolol) Receives the US FDA’s Approval for Atrial Fibrillation and Atrial Flutter in the Critical Care S...

  • November 28, 2024
BeiGene’s (to be BeOne Medicines) Tevimbra Secures the EC’s Approval as a 1L Treatment of Esophageal Squamous Cell Carcinoma and G/GEJ Cancer

BeiGene’s (to be BeOne Medicines) Tevimbra Secures the EC’s Approval as a 1L Treatment of Esophageal Squamous Cell Carcinoma and G...

  • November 28, 2024
UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

  • November 21, 2024
Jaguar Health Reports the US FDA’s Renewal of Conditional Approval for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health Reports the US FDA’s Renewal of Conditional Approval for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dog...

  • November 7, 2024
Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

  • October 24, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.